Veeva Systems (VEEV) FY Conference June 04, 2025 02:20 PM ET Speaker0 Awesome. Speaker1 Good. Oh, Speaker0 yep. Thank you, everybody. Appreciate, your time and attention here. My name is Dylan Becker. I'm the research analyst here, at William Blair that covers Viva Systems. We have the CFO, Brian with us today. For all of the necessary disclosures with today's presentation, you can find those at at WilliamBlair.com. But, Brian, thank you for joining us. Speaker1 Thanks for having us. Speaker0 There's there' ...

Core Insights - Veeva Systems and Sarah Cannon Research Institute (SCRI) have formed a strategic collaboration to enhance the efficiency of oncology clinical trials across SCRI's 200+ research sites [1][2] - The adoption of Veeva Clinical Platform aims to unify SCRI's contract research organization (CRO) and site management organization (SMO) for improved data flow and trial processes [1][2] Company Overview - Sarah Cannon Research Institute is a leading oncology research organization with a focus on community-based clinical trials, having conducted over 850 first-in-human clinical trials and contributed to the majority of new cancer therapies approved by the FDA in the last decade [4] - Veeva Systems is recognized as the global leader in cloud software for the life sciences industry, serving over 1,000 customers, including major biopharmaceutical companies and emerging biotechs [5] Technology and Innovation - The Veeva Clinical Platform is a comprehensive solution that integrates various clinical operations and data applications, streamlining the clinical trial process from start to finish [3] - The collaboration is expected to standardize operations on a single platform, enabling SCRI to deliver faster and more cost-effective clinical trials [3]

BURLINGAME, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Today, Accumulus Synergy (“Accumulus”) announced a strategic partnership with Veeva Systems (“Veeva”) focused on enabling connectivity to help the life sciences industry more effectively exchange regulated information with national regulatory authorities (NRAs) around the world. The partnership aims to empower customers with the tools needed to meet today’s regulatory interoperability demands while maintaining the flexibility to adapt to the evolving reg ...

Veeva Systems Inc. (NYSE:VEEV) Baird Global Consumer, Technology & Services Conference Call June 3, 2025 10:50 AM ET Company Participants Paul Shawah - Executive Vice President of Strategy & Campaign Manager Conference Call Participants Joseph D. Vruwink - Robert W. Baird & Co. Incorporated, Research Division Joseph D. Vruwink is the leader in cloud software for the life sciences industry across both commercial and R&D solutions. Joining us today is Paul Shawah. He is EVP of Strategy at Veeva. This is going ...

Veeva Systems (VEEV) 2025 Conference June 03, 2025 10:50 AM ET Speaker0 Hi, everyone. I'm Joe Verwink. I cover vertical software at Baird. Our next presentation is from Veeva. Veeva is the leader in cloud software for the life sciences industry across both commercial and R and D solutions. Joining us today is Paul Shawa. He is EVP of Strategy at Veeva. This is going to be a fireside chat format. If members of the audience have questions, you can email session1@rwBaird, and I'll read those on the iPad. But m ...

Have you evaluated the performance of Veeva Systems' (VEEV) international operations during the quarter that concluded in April 2025? Considering the extensive worldwide presence of this provider of cloud-based software services for the life sciences industry, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivot ...

Financial Performance - Total revenues for the three months ended April 30, 2025, were $759,043,000, representing a 16.7% increase from $650,345,000 in the same period of 2024[18]. - Subscription services revenue increased to $634,768,000, up 18.9% from $533,955,000 year-over-year[18]. - Net income for the quarter was $228,190,000, a 41.1% increase compared to $161,664,000 in the prior year[18]. - Operating income rose to $233,732,000, reflecting a 50.5% increase from $155,172,000 in the same quarter of 2024[18]. - The company reported a gross profit of $585,219,000, which is a 22.8% increase from $476,461,000 in the same quarter last year[18]. - Net cash provided by operating activities was $877,158,000, compared to $763,516,000 for the same period in 2024, marking a 14.9% increase[24]. - The company generated net income of $714 million for the fiscal year ended January 31, 2025, representing a 35.7% increase from $526 million in 2024[80]. Assets and Equity - Cash and cash equivalents at the end of the period were $1,964,982,000, up from $1,118,785,000 at the beginning of the year[15]. - Total assets increased to $7,765,077,000, compared to $7,339,756,000 as of January 31, 2025[15]. - Stockholders' equity grew to $6,211,098,000, up from $5,832,373,000 at the end of the previous quarter[15]. - Veeva's total available-for-sale securities amounted to $4,103,435 thousand as of April 30, 2025, with a gross unrealized gain of $31,083 thousand and unrealized losses of $2,050 thousand[32]. Expenses - Research and development expenses were $184,033,000, an increase of 13.1% from $162,711,000 in the prior year[18]. - Sales and marketing expenses increased slightly to $98,628 thousand, a 1% rise from $97,301 thousand, driven by higher employee compensation costs[107]. - General and administrative expenses increased by 12% to $68,826 thousand, primarily due to a $10 million rise in employee compensation-related costs[109]. Tax and Income Per Share - The effective tax rate for the three months ended April 30, 2025, was 23.6%, up from 21.9% in the prior year, primarily due to reduced future benefits from non-deductible compensation[44]. - Basic net income per share increased to $1.40 for the three months ended April 30, 2025, up from $1.00 in the same period of 2024, a 40% increase[60]. Customer and Market Insights - North America generated $459,467 thousand in revenues for the three months ended April 30, 2025, a 20.4% increase from $381,599 thousand in 2024[71]. - R&D Solutions accounted for 54% of total revenues for the three months ended April 30, 2025, while Commercial Solutions accounted for 46%[79]. - The company served 1,477 customers as of January 31, 2025, an increase from 1,432 customers in 2024[81]. Risks and Challenges - The company faces risks related to cybersecurity, including potential breaches that could harm customer trust and lead to significant liabilities[153]. - The markets for the company's solutions are highly competitive, with significant competition from firms like Salesforce and IQVIA[160]. - The company is subject to changing laws and regulations, which may impose additional compliance costs and liabilities[158]. - The company faces risks related to international operations, including regulatory, economic, and political challenges[171]. Compliance and Regulatory Environment - Compliance with complex regulations in the life sciences industry is essential; failure to comply could lessen demand for solutions and expose the company to significant claims[193]. - Increasingly complex data protection regulations, such as the EU GDPR, impose significant obligations and potential penalties for non-compliance, affecting operational costs[199]. - The company anticipates ongoing evolution of privacy and data protection laws, which will require continuous compliance efforts and could lead to increased operational complexity[201]. Strategic Initiatives - The company announced the launch of Veeva AI, integrating AI across major application areas, which may introduce new risks and challenges affecting adoption[207]. - The company expects R&D Solutions revenues to increase as a percentage of total revenues in the future[79].

Group 1 - The article discusses Veeva (NYSE: VEEV) and reiterates a "buy" rating for 2025 with a price target of $286 per share [1] - The author emphasizes the importance of investing in sustainable, growth-driven companies that maximize shareholder equity [1] - The article highlights the author's background in high-growth supply-chain start-ups and experience with venture capital firms, which contributed to maximizing returns for clients during the pandemic [1] Group 2 - The author has a beneficial long position in VEEV shares through stock ownership, options, or other derivatives [2] - The article expresses the author's personal opinions and does not involve compensation from any company mentioned [2] - Seeking Alpha clarifies that past performance is not indicative of future results and that the views expressed may not reflect those of the platform as a whole [3]

Veeva Systems Inc. VEEV posted better-than-expected earnings for the first quarter and raised the outlook on Wednesday.The company reported adjusted earnings per share of $1.97, beating the analyst consensus estimate of $1.77. Quarterly sales of $759 million (+17% year over year) outpaced the Street view of $731.91 million."We crossed our 2025 revenue run rate goal this quarter and are progressing well toward our 2030 goal to double that and the positive impact we can have for our customers and the industry ...

Veeva Systems, Inc. (VEEV) reported adjusted earnings per share (EPS) of $1.97 for the first quarter of fiscal 2026, which increased 31.3% from the year-ago figure of $1.50. Adjusted EPS surpassed the Zacks Consensus Estimate by 13.22%. (Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.)GAAP EPS in the fiscal first quarter was $1.37, up 39.8% from the year-ago period’s 98 cents.VEEV’s Revenue DetailsIn the quarter under review, the company’s revenues totaled $759 million, outpacing t ...